Over the past year, the BIOSECURE Act has transitioned from legislative debate to enacted federal law. The significance of this development lies not merely in the fact of enactment, but in the shift it represents: companies are no longer assessing a hypothetical proposal, but rather preparing for a structured, phased implementation framework.
This article consolidates regulatory developments accumulated over the past year and outlines key considerations for companies from an operational and industry perspective. Rather than providing legal advice or statutory interpretation, the focus is on identifying structural elements that companies may wish to reassess in light of the evolving regulatory environment.
From Enactment to Implementation
The BIOSECURE Act was signed into law on December 18, 2025, as part of the National Defense Authorization Act (NDAA). While the statute is now in effect, implementation is expected to proceed in stages.
Based on publicly available information, the anticipated framework includes the following timeline structures:
- Within approximately one year of enactment: Publication of an initial list of designated “Biotechnology Companies of Concern” by the Office of Management and Budget (OMB);
- Within approximately 180 days thereafter: Issuance of implementing guidance;
- Within the following year: Amendments to the Federal Acquisition Regulation (FAR); and
- Thereafter: Phased application of federal procurement restrictions.
Accordingly, with the law enacted, companies are now entering a preparatory phase in which implementation timing and regulatory structure warrant careful review.
Core Structural Feature: Designation and Federal Nexus, Not Nationality
The BIOSECURE Act is structured around the designation of specific “Biotechnology Companies of Concern” and restrictions tied to federal procurement and federal funding. It does not operate as a blanket restriction based solely on corporate nationality.
As a result, when evaluating potential exposure, companies may find it more useful to assess structural connections rather than geographic location. Relevant considerations may include:
- Whether the company maintains commercial or contractual relationships with designated entities;
- The extent of reliance on third-party manufacturing arrangements (including contract development and manufacturing organizations, or CDMOs);
- Use of contract research organizations (CROs) or other outsourced laboratory infrastructure; and
- Connections to federal research funding or federal contracts.
These structural elements often intersect directly with supply chain configuration and funding streams, and therefore, may become central to a company’s internal review process.
Manufacturing and Supply Chain Considerations
For therapeutics companies that either conduct manufacturing in-house or rely on third-party manufacturers, supply chain structure may have implications beyond contractual substitution.
Manufacturing transitions can implicate:
- Site-specific regulatory approvals;
- Good manufacturing practice (GMP) revalidation requirements;
- Technology transfer timelines; and
- Capacity constraints among alternative suppliers.
Accordingly, any assessment of potential impact may need to account not only for the statutory language of the Act, but also for the operational realities of manufacturing continuity and regulatory compliance.
Federal Funding Linkages
Because the BIOSECURE Act is tied to federal procurement and funding mechanisms, its potential implications are not limited to companies that directly sell products to federal agencies.
Companies engaged in activities supported by federal funding—such as grants from the National Institutes of Health (NIH), research funding from the Department of Defense (DoD), or other federal programs—may wish to evaluate how those funding structures interface with supply chain relationships.
In practice, the relevant inquiry may extend beyond whether a company is a federal contractor, and instead, encompass how federal funding is embedded within the company’s broader operational framework.
Transition Periods and Market Dynamics
Public summaries suggest that certain pre-existing contracts may benefit from transition or grandfathering provisions under defined conditions. However, such transition periods do not necessarily eliminate longer-term structural considerations.
Market behavior—including investor diligence, procurement standards, and contractual representations—may evolve in advance of formal regulatory deadlines. For that reason, transition windows may function less as a period of regulatory relief and more as an opportunity for structured internal review and contingency planning.
Practical Considerations for 2026
From an operational perspective, companies may consider:
- Supply chain mapping
- Identifying key manufacturing and research partners;
- Reviewing subcontractor layers where feasible;
- Evaluating intersections with federal funding.
- Transition feasibility assessment
- Availability of alternative suppliers;
- Regulatory implications of site changes;
- Estimated timelines and associated costs.
- Milestone-based review triggers
- Publication of the initial OMB designation list;
- Issuance of implementing guidance;
- Finalization of FAR amendments.
Predefining internal review steps tied to these milestones may support more measured and systematic responses.
Conclusion: A Moment for Structural Reassessment
The BIOSECURE Act may be viewed less as an immediate disruption and more as a catalyst for reassessing supply chain transparency and federal funding exposure within the life sciences sector.
In sum, as of 2026:
- The law has been enacted;
- Implementation is expected to unfold in stages;
- Companies may benefit from reviewing supply chain and funding structures in light of potential designation and procurement implications.
Rather than speculating about future designations, a disciplined evaluation of structural exposure may represent the most constructive next step.
Because the applicability and strategic response will vary depending on a company’s specific business model, contractual relationships, and funding structure, further tailored legal and regulatory analysis may be appropriate. In particular, companies with complex federal procurement interfaces, layered supply chains, or federally supported research activities may wish to consider a more detailed review based on their particular facts.
